Eslicarbazepine and Kisqali Femara Co-Pack 600 mg-2.5 mg Dose
Determining the interaction of Eslicarbazepine and Kisqali Femara Co-Pack 600 mg-2.5 mg Dose and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Ribociclib may increase the blood levels and effects of letrozole. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to ribociclib-mediated inhibition of CYP450 3A4 metabolism. In healthy study subjects, administration of midazolam, a sensitive CYP450 3A4 substrate, with multiple 400 mg daily doses of ribociclib increased the midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) by 2.1-fold and 3.8-fold, respectively, compared to midazolam administered alone. When given at a clinically relevant dose of 600 mg daily, ribociclib is predicted to increase midazolam Cmax and AUC by 2.4-fold and 5.2-fold, respectively.
MANAGEMENT: Caution is advised when ribociclib is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ribociclib is added to or withdrawn from therapy.
- Trivier JM, Libersa C, Belloc C, Lhermitte M "Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report)." Life Sci 52 (1993): pl91-6
- Rawden HC, Kokwaro GO, Ward SA, Edwards G "Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes." Br J Clin Pharmacol 49 (2000): 313-22
- Kane GC, Lipsky JJ "Drug-grapefruit juice interactions." Mayo Clin Proc 75 (2000): 933-42
- Katoh M, Nakajima M, Yamazaki H, Yokoi T "Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport." Eur J Pharm Sci 12 (2001): 505-13
- DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4
- "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.
- Yu DK "The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions." J Clin Pharmacol 39 (1999): 1203-11
- Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R "Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions." Biochem Pharmacol 45 (1993): 853-61
- Nagy J, Schipper HG, Koopmans RP, Butter JJ, van Boxtel CJ, Kager PA "Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability." Am J Trop Med Hyg 66 (2002): 260-3
Generic Name: eslicarbazepine
Brand name: Aptiom
Synonyms: n.a.
Generic Name: letrozole / ribociclib
Brand name: Kisqali Femara Co-Pack 200 mg-25 mg Dose, Kisqali Femara Co-Pack 400 mg-25 mg Dose, Kisqali Femara Co-Pack 600 mg-25 mg Dose
Synonyms: Kisqali Femara Co-Pack 200 mg-2.5 mg Dose, Kisqali Femara Co-Pack
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Eslicarbazepine-Kitabis Pak
- Eslicarbazepine-Kitabis Pak inhalation
- Eslicarbazepine-Klofensaid II
- Eslicarbazepine-Klonopin
- Eslicarbazepine-Klonopin Wafer
- Eslicarbazepine-Klonopin Wafers
- Kisqali Femara Co-Pack 600 mg-2.5 mg Dose-Eslicarbazepine Acetate
- Kisqali Femara Co-Pack 600 mg-2.5 mg Dose-Esmolol
- Kisqali Femara Co-Pack 600 mg-2.5 mg Dose-Esmolol HCl
- Kisqali Femara Co-Pack 600 mg-2.5 mg Dose-Esmolol Hydrochloride
- Kisqali Femara Co-Pack 600 mg-2.5 mg Dose-Esmolol Injection
- Kisqali Femara Co-Pack 600 mg-2.5 mg Dose-Esmolol Intravenous